Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002
Intellia Therapeutics (NTLA) announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE).
About Hereditary . . .
This content is for paid subscribers.
Today’s Highlights October 6, 2021